Trial Profile
Efficacy of olaparib in patients with breast cancer and a germline BRCA1/2 mutation
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2015
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms Neo-Olympia
- 24 Mar 2015 New trial record